Medicines & Healthcare products Regulatory Agency

MHRA
Regulating Medicines and Medical Devices

[redacted]

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

www.gov.uk/mhra

11th July 2023

Dear [redacted]

FOI 23/164

Thank you for your email dated 22nd February 2023, where you requested information held by the MHRA relating to the CPRD study "Near real time vaccine safety monitoring for COVID-19 vaccines". Apologies for the delay in responding to you on this request.

Specifically you asked, would you be able to provide all versions of the protocol for this study.

The protocol and reports from this study will be published in the future and thus provision of this information is exempt under Section 22 of the FOI Act. Section 22 of the Act allows public authorities to refuse requests where the authority intends to publish the information at a future date. This study will be published in a peer reviewed journal.

Yours sincerely,

FOI Team,
Safety and Surveillance Group

If you have a query about this email, please contact us. If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your request. If you wish to pursue that option please write to the Communications Directorate, 4-T, Medicines and Healthcare products Regulatory Agency, (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at:

Medicines & Healthcare products Regulatory Agency

MHRA
Regulating Medicines and Medical Devices

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF